Elevance Health Inc (ELV · NYSE)

ELV · MARKET VIEW

Market view · as of Aug 3, 2026

Revenue (TTM)
$201.11B
+1.4% YoY
Gross margin
26.0%
EPS (latest q)
$7.45
vs $6.18 est · beat
52-wk position
67.7%
-11.9% vs 52w high · -10.1% 1mo

Price (last ~year)

Elevance Health shares have declined 10.1% over the past month amid stalled contract negotiations with Sentara Health, despite the company reporting Q2 2026 revenue of $50.47 billion and its fourth consecutive earnings beat. The health benefits provider currently trades at $375.84 with a 16.61 P/E ratio and $31.04 billion in total debt.

Valuation

Market cap
$81.51B
P/E
16.61
PEG
1.331
P/B
1.816
P/S
0.405
Beta
0.683
Analyst target
$449.1

Quality & returns

Gross margin
26.0%
Operating margin
4.6%
Profit margin
2.5%
ROE
11.1%
ROA
3.8%

Price movement

Last
$375.84
1-month
-10.1%
3-month
+2.3%
RSI (14)
28
vs SMA200
+7.8%
52-wk position
67.7% -11.9% vs high

Quarterly trajectory

Revenue by quarter (oldest → newest)

QuarterRevenueOp incomeNet incomeEBITDA
2026-06-30$50.47B$2.06B$1.46B$2.10B
2026-03-31$50.18B$2.66B$1.76B$2.77B
2025-12-31$49.75B$581.0M$547.0M$987.0M
2025-09-30$50.71B$1.76B$1.19B$2.14B

Recent news

Sources this view read

  • fundamentals Company overview & valuation (Alpha Vantage OVERVIEW)
  • filing Quarterly financial statements (Alpha Vantage INCOME/BALANCE/CASH)
  • earnings Reported earnings history (Alpha Vantage EARNINGS)
  • prices Adjusted daily prices (Alpha Vantage TIME_SERIES_DAILY_ADJUSTED)

Other snapshots